C. Scully and J. Bagan, Oral squamous cell carcinoma overview, Oral Oncology, vol.45, issue.4-5, pp.301-308, 2009.
DOI : 10.1016/j.oraloncology.2009.01.004

P. Amornphimoltham, V. Patel, A. Sodhi, N. Nikitakis, and J. Sauk, Mammalian target of rapamycin, a molecular target in squamous cell

S. Warnakulasuriya, Global epidemiology of oral and oropharyngeal cancer, Oral Oncology, vol.45, issue.4-5, pp.309-316, 2009.
DOI : 10.1016/j.oraloncology.2008.06.002

J. Shah and Z. Gil, Current concepts in management of oral cancer ??? Surgery, Oral Oncology, vol.45, issue.4-5, pp.394-401, 2009.
DOI : 10.1016/j.oraloncology.2008.05.017

N. Beech, S. Robinson, S. Porceddu, and M. Batstone, Dental management of patients irradiated for head and neck cancer, Australian Dental Journal, vol.49, issue.3 Suppl, pp.20-28, 2014.
DOI : 10.1111/adj.12134

B. Chaveli-lopez, Oral toxicity produced by chemotherapy: A systematic review, Journal of Clinical and Experimental Dentistry, vol.6, pp.81-90, 2014.
DOI : 10.4317/jced.51337

A. Watters, J. Epstein, and M. Agulnik, Oral complications of targeted cancer therapies: A narrative literature review, Oral Oncology, vol.47, issue.6, pp.441-448, 2011.
DOI : 10.1016/j.oraloncology.2011.03.028

T. Strom, A. Trotti, J. Kish, J. Russell, and N. Rao, Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer, Oral Oncology, vol.51, issue.7, pp.704-708, 2015.
DOI : 10.1016/j.oraloncology.2015.04.012

N. Saba, S. Hurwitz, K. Magliocca, S. Kim, and T. Owonikoko, Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck, Cancer, vol.51, issue.24, pp.3940-3951, 2014.
DOI : 10.1002/cncr.28965

A. Molinolo, P. Amornphimoltham, C. Squarize, R. Castilho, and V. Patel, Dysregulated molecular networks in head and neck carcinogenesis, Oral Oncology, vol.45, issue.4-5, pp.324-234, 2009.
DOI : 10.1016/j.oraloncology.2008.07.011

C. Aktipis, V. Kwan, K. Johnson, S. Neuberg, and C. Maley, Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research, PLoS ONE, vol.32, issue.30
DOI : 10.1371/journal.pone.0026100.t002

J. Shim and J. Liu, Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs, International Journal of Biological Sciences, vol.10, issue.7, pp.654-663, 2014.
DOI : 10.7150/ijbs.9224

T. Ashburn and T. Kb, Drug repositioning: identifying and developing new uses for existing drugs, Nature Reviews Drug Discovery, vol.2, issue.8, pp.673-683, 1038.
DOI : 10.1038/nrd1468

M. Tuorkey, Molecular targets of luteolin in cancer, European Journal of Cancer Prevention, vol.25, issue.1, 2015.
DOI : 10.1097/CEJ.0000000000000128

X. Liu, F. Ye, J. Wu, B. How, and W. Li, Signaling Proteins and Pathways Affected by Flavonoids in Leukemia Cells, Nutrition and Cancer, vol.25, issue.2, pp.238-249, 2015.
DOI : 10.1080/01635589809514701

S. Tu, C. Ho, M. Liu, C. Huang, and H. Chang, Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression, Food Chemistry, vol.141, issue.2, pp.1553-1561, 2013.
DOI : 10.1016/j.foodchem.2013.04.077

C. Kandaswami, L. Lee, P. Lee, J. Hwang, and F. Ke, The antitumor activities of flavonoids, In Vivo, vol.19, pp.895-909, 2005.

Y. Lin, R. Shi, X. Wang, and H. Shen, Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy, Current Cancer Drug Targets, vol.8, issue.7, pp.634-646, 2008.
DOI : 10.2174/156800908786241050

G. Seelinger, I. Merfort, U. Wolfle, and C. Schempp, Anti-carcinogenic Effects of the Flavonoid Luteolin, Molecules, vol.13, issue.12, pp.2628-2651, 2008.
DOI : 10.3390/molecules13102628

C. Weng and Y. Gc, Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities, Cancer and Metastasis Reviews, vol.281, issue.1-2, pp.323-351
DOI : 10.1007/s10555-012-9347-y

M. Krifa, L. Leloup, K. Ghedira, M. Mousli, and L. Chekir-ghedira, Luteolin Induces Apoptosis in BE Colorectal Cancer Cells by Downregulating Calpain, UHRF1, and DNMT1 Expressions, Nutrition and Cancer, vol.137, issue.7, pp.1220-1227, 2014.
DOI : 10.1007/s11010-008-9749-x

H. Luo, B. Jiang, S. King, and Y. Chen, Inhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids, Nutrition and Cancer, vol.41, issue.6, pp.800-809, 2008.
DOI : 10.1080/01635580802100851

J. Dwyer, J. Hebda, L. Guelte, A. Galan-moya, E. Smith et al., Glioblastoma Cell-Secreted Interleukin-8 Induces Brain Endothelial Cell Permeability via CXCR2, PLoS ONE, vol.7, issue.9
DOI : 10.1371/journal.pone.0045562.t001

L. Guelte, A. Galan-moya, E. Dwyer, J. Treps, L. Kettler et al., Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation, Journal of Cell Science, vol.125, issue.17, pp.4137-4146, 2012.
DOI : 10.1242/jcs.108282

A. Sancar, L. Lindsey-boltz, K. Unsal-kaçmaz, and L. S. , Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints, Annual Review of Biochemistry, vol.73, issue.1, pp.39-85, 2004.
DOI : 10.1146/annurev.biochem.73.011303.073723

A. Amin, D. Wang, H. Zhang, S. Peng, and H. Shin, Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (-)-Epigallocatechin-3-gallate and Luteolin: POTENTIAL ROLE OF p53, Journal of Biological Chemistry, vol.285, issue.45, pp.34557-34565, 2010.
DOI : 10.1074/jbc.M110.141135

D. Majumdar, K. Jung, H. Zhang, S. Nannapaneni, and X. Wang, Luteolin Nanoparticle in Chemoprevention: In Vitro and In Vivo Anticancer Activity, Cancer Prevention Research, vol.7, issue.1, pp.65-73, 2014.
DOI : 10.1158/1940-6207.CAPR-13-0230

O. Prey, J. Brown, J. Fleming, J. Harrison, and P. , Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells, Biochem Pharmacol, vol.66, pp.2075-2088, 2003.

L. Verschooten, K. Barrette, S. Van-kelst, R. Romero, N. Proby et al., Autophagy Inhibitor Chloroquine Enhanced the Cell Death Inducing Effect of the Flavonoid Luteolin in Metastatic Squamous Cell Carcinoma Cells, PLoS ONE, vol.49, issue.10
DOI : 10.1371/journal.pone.0048264.g005

S. Yang, W. Yang, H. Chang, S. Chu, and Y. Hsieh, Luteolin Induces Apoptosis in Oral Squamous Cancer Cells, Journal of Dental Research, vol.87, issue.4, pp.401-406, 2008.
DOI : 10.1177/154405910808700413

A. Brockmann, T. Strittmatter, S. May, K. Stemmer, and A. Marx, Structure???Function Relationship of Thiazolide-Induced Apoptosis in Colorectal Tumor Cells, ACS Chemical Biology, vol.9, issue.7, pp.1520-1527, 2014.
DOI : 10.1021/cb500209a

J. Muller, D. Sidler, U. Nachbur, J. Wastling, and T. Brunner, -transferase Pi (GSTP1)-dependent cell death in human colon cancer cells, International Journal of Cancer, vol.97, issue.8, pp.1797-1806, 2008.
DOI : 10.1002/ijc.23755

URL : https://hal.archives-ouvertes.fr/hal-00408926

W. Senkowski, X. Zhang, H. Olofsson, M. Isacson, R. Hoglund et al., Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer, Molecular Cancer Therapeutics, vol.14, issue.6, pp.1504-1516
DOI : 10.1158/1535-7163.MCT-14-0792

D. Sidler, A. Brockmann, J. Mueller, U. Nachbur, and N. Corazza, Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase???Bim axis and reveals glutathione-S-transferase P1 as Achilles??? heel, Oncogene, vol.60, issue.37, pp.4095-4106575, 2011.
DOI : 10.1038/nrm2308

H. Fan-minogue, S. Bodapati, D. Solow-cordero, A. Fan, and R. Paulmurugan, A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide, Molecular Cancer Therapeutics, vol.12, issue.9, pp.1896-1905
DOI : 10.1158/1535-7163.MCT-12-1243

K. Kang, S. Park, D. Kim, M. Sung, and Y. Jung, Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis, Nephrology Dialysis Transplantation, vol.26, issue.3, pp.814-822, 2011.
DOI : 10.1093/ndt/gfq528

A. Levy, D. Felice, F. Bellefqih, S. Guigay, J. Deutsch et al., Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer, Head & Neck, vol.16, issue.suppl, 2015.
DOI : 10.1002/hed.24125

J. Johnson and E. Gonzalez-de-mejia, Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro, Food and Chemical Toxicology, vol.60, pp.83-91, 2013.
DOI : 10.1016/j.fct.2013.07.036

R. Shi, Q. Huang, X. Zhu, Y. Ong, and B. Zhao, Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization, Molecular Cancer Therapeutics, vol.6, issue.4, pp.1338-1347, 2007.
DOI : 10.1158/1535-7163.MCT-06-0638

S. Chian, Y. Li, X. Wang, and X. Tang, Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway, Asian Pacific Journal of Cancer Prevention, vol.15, issue.6, pp.2911-2916, 2014.
DOI : 10.7314/APJCP.2014.15.6.2911

B. Markaverich, M. Vijjeswarapu, K. Shoulars, and M. Rodriguez, Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells, The Journal of Steroid Biochemistry and Molecular Biology, vol.122, issue.4, pp.219-231, 2010.
DOI : 10.1016/j.jsbmb.2010.06.006

M. Sakurai, Y. Ozaki, D. Okuzaki, Y. Naito, and T. Sasakura, Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin G-Associated Kinase and Induction of miR-630, PLoS ONE, vol.98, issue.6
DOI : 10.1371/journal.pone.0100124.s009

J. Menendez, A. Vazquez-martin, C. Oliveras-ferraros, R. Garcia-villalba, and A. Carrasco-pancorbo, Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays, International Journal of Molecular Medicine, vol.22, issue.4, pp.433-439, 2008.
DOI : 10.3892/ijmm_00000039

B. Wu, Q. Zhang, W. Shen, and J. Zhu, Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line, Molecular and Cellular Biochemistry, vol.7, issue.Suppl 3, pp.125-132, 2008.
DOI : 10.1007/s11010-008-9749-x

S. Chian, R. Thapa, C. Z. Wang, X. Tang, and X. , Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo, Biochemical and Biophysical Research Communications, vol.447, issue.4, pp.602-608, 2014.
DOI : 10.1016/j.bbrc.2014.04.039

Z. Hong, X. Cao, N. Li, Y. Zhang, and L. Lan, Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance, British Journal of Pharmacology, vol.56, issue.11, pp.2842-2853, 2014.
DOI : 10.1111/bph.12610

S. Zabludoff, C. Deng, M. Grondine, A. Sheehy, and S. Ashwell, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Molecular Cancer Therapeutics, vol.7, issue.9, pp.2955-2966, 2008.
DOI : 10.1158/1535-7163.MCT-08-0492

S. Tang, D. Xu, and B. Zhou, Analysis of P53 mutation and invasion front grading in oral squamous cell carcinomas, Journal of Huazhong University of Science and Technology [Medical Sciences], vol.34, issue.10, pp.525-529, 2010.
DOI : 10.1007/s11596-010-0462-0

J. Ries, D. Schreiner, H. Steininger, and S. Girod, mutation and detection of p53 protein expression in oral leukoplakia and oral squamous cell carcinoma, Anticancer Res, vol.18, pp.53-2031, 1998.

H. Lee, Y. Kang, J. Lee, J. Byun, and U. Kim, Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma, BMC Oral Health, vol.52, issue.1, 2015.
DOI : 10.1371/journal.pone.0003360

Y. Yamazaki, I. Chiba, A. Hirai, C. Sugiura, and K. Notani, Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma, Oral Oncology, vol.39, issue.2, pp.163-169, 2003.
DOI : 10.1016/S1368-8375(02)00064-7

N. Siegelmann-danieli, O. Ben-izhack, A. Hanlon, J. Ridge, and M. Stein, P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure, Tumori, vol.91, pp.346-350, 2005.

R. Kozomara, N. Jovic, Z. Magic, M. Brankovic-magic, and V. Minic, p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival, Journal of Cranio-Maxillofacial Surgery, vol.33, issue.5, pp.53-342, 2005.
DOI : 10.1016/j.jcms.2005.05.004

A. Ramos, C. Pereira-wilson, and C. Ar, Protective effects of Ursolic acid and Luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.692, issue.1-2, 2010.
DOI : 10.1016/j.mrfmmm.2010.07.004